Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics
Phase 4
Completed
- Conditions
- Pain
- Registration Number
- NCT00198549
- Lead Sponsor
- Bausch & Lomb Incorporated
- Brief Summary
The purpose of this study is to evaluate Vitrase as an adjuvant to increase absorption and dispersion of other injected anesthetics
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Scheduled for an ophthalmic surgical procedure
Exclusion Criteria
- Known allergy to bee venom
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To evaluate physician acceptance of efficacy of Vitrase as an adjuvant to increase absorption and dispersion of anesthetics used for ophthalmic surgical procedures
- Secondary Outcome Measures
Name Time Method To determine physician usage of and satisfaction with Vitrase in the 6200 USP unit vial
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Vitrase utilize to enhance anesthetic dispersion in ophthalmic surgery?
How does Vitrase compare to standard-of-care adjuvants in ophthalmic anesthetic absorption efficacy?
Are there specific biomarkers that predict optimal Vitrase response in pain management during eye procedures?
What adverse events are associated with Vitrase use as an anesthetic adjuvant and how are they managed?
What other hyaluronidase-based compounds are being explored for ophthalmic anesthetic enhancement?
Trial Locations
- Locations (1)
Cincinnati Eye Institute
🇺🇸Cincinnati, Ohio, United States
Cincinnati Eye Institute🇺🇸Cincinnati, Ohio, United States